Ignite Creation Date:
2024-05-05 @ 6:32 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00492336
Status:
COMPLETED
Last Update Posted:
2019-09-25
First Post:
2007-06-26
Brief Title:
Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia
Sponsor:
University of Maryland Baltimore
Organization:
University of Maryland Baltimore
Study Overview
Official Title:
Rasagiline in the Treatment of Persistent Negative Symptoms of Schizophrenia
Status:
COMPLETED
Status Verified Date:
2013-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a study of a new medication for the treatment of cognitive impairments thinking difficulties and negative symptoms in people with schizophrenia The new medication is rasagiline Rasagiline is a drug which has been approved by the Food and Drug Administration for the treatment of Parkinsons disease It is used to treat cognitive problems
Detailed Description:
The study will consist of two phases a 4-week continued stability phase lead-in phase and a 12-week double-blind treatment phase In the lead-in phase subjects receiving antipsychotic medication who manifest moderate to severe and persistent negative symptoms will remain on their maintenance regimen for at least four weeks The treatment phase will be a 12-week parallel groups double-blind placebo-controlled trial of adjunctive rasagiline 1 mgday a selective MAO-B oxidase inhibitor
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| H-27877 | OTHER | University of Maryland Baltimore | None |